Skip to main content

Table 1 Cumulative biodistribution data of [111In-DOTA]MG11 in AR42J tumor-bearing SCID mice including controls and animals treated with NEP and/or ACE inhibitors

From: Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [111In-DOTA]MG11—first estimates for clinical translation

Organs [111In-DOTA]MG11 (%ID/g tissue ± SD at 4 h pi, n ≥ 4)
+DG2 + PAa Control +Lisb +PAc +PA + Lisd +TOe +Racef
Blood 0.02 ± 0.01 0.04 ± 0.01 0.05 ± 0.02 0.06 ± 0.04 0.05 ± 0.02 0.02 ± 0.01 0.20 ± 0.08
Liver 0.14 ± 0.02 0.13 ± 0.03 0.13 ± 0.01 0.15 ± 0.04 0.17 ± 0.09 0.17 ± 0.05 1.19 ± 0.03
Heart 0.02 ± 0.01 0.05 ± 0.02 0.05 ± 0.01 0.07 ± 0.03 0.07 ± 0.03 0.03 ± 0.02 0.13 ± 0.03
Kidneys 1.31 ± 0.03 1.86 ± 0.25 1.85 ± 0.30 2.26 ± 0.33 1.82 ± 0.06 2.95 ± 0.80 1.93 ± 0.46
Stomach 0.08 ± 0.01 1.53 ± 0.65 2.83 ± 0.68 5.13 ± 2.29 6.21 ± 2.73 2.90 ± 0.51 4.60 ± 1.09
Intestines 0.48 ± 0.08 0.89 ± 0.76 0.65 ± 0.25 0.69 ± 0.13 0.82 ± 0.26 2.16 ± 0.88 0.83 ± 0.12
Spleen 0.09 ± 0.02 0.17 ± 0.07 0.34 ± 0.30 0.20 ± 0.08 0.30 ± 0.13 0.14 ± 0.04 0.30 ± 0.06
Muscle 0.01 ± 0.01 0.04 ± 0.01 0.04 ± 0.01 0.09 ± 0.17 0.07 ± 0.04 0.02 ± 0.01 0.10 ± 0.03
Lung 0.05 ± 0.01 0.07 ± 0.02 0.07 ± 0.01 0.10 ± 0.01 0.28 ± 0.19 0.12 ± 0.05 0.12 ± 0.03
Femur 0.04 ± 0.01 0.09 ± 0.05 0.08 ± 0.01 0.12 ± 0.06 0.15 ± 0.04 0.05 ± 0.01 0.26 ± 0.22
Pancreas 0.08 ± 0.01 0.11 ± 0.03 0.18 ± 0.09 0.36 ± 0.17 0.53 ± 0.24 0.30 ± 0.16 0.30 ± 0.061
Tumor 0.34 ± 0.04 1.82 ± 1.25 1.80 ± 0.74 15.32 ± 4.71 14.51 ± 4.73 12.32 ± 3.66 6.81 ± 2.79
  1. aCoinjection of 50 nmol DG2 [25] and 300 μg PA to assess non-specific tumor uptake
  2. bCoinjection of 100 μg Lis
  3. cCoinjection with 300 μg PA
  4. dCoinjection with 300 μg PA and 100 μg Lis
  5. eCoinjection with 150 μg TO
  6. fRadiotracer injection 30–40 min after ip injection of 3 mg Race